Healthcare resource utilization patterns in psoriasis patients using biologic and conventional treatments in Finland
Vesikansa, Aino; Mehtälä, Juha; Aaltonen, Jaakko; Konttinen, Riikka; Tasanen, Kaisa; Huilaja, Laura (2024-06-10)
Frontiers media
10.06.2024
Vesikansa A, Mehtälä J, Aaltonen J, Konttinen R, Tasanen K and Huilaja L (2024) Healthcare resource utilization patterns in psoriasis patients using biologic and conventional treatments in Finland. Front. Immunol. 15:1374829. doi: 10.3389/fimmu.2024.1374829
https://creativecommons.org/licenses/by/4.0/
© 2024 Vesikansa, Mehtälä, Aaltonen, Konttinen, Tasanen and Huilaja. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by/4.0/
© 2024 Vesikansa, Mehtälä, Aaltonen, Konttinen, Tasanen and Huilaja. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by/4.0/
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202406264944
https://urn.fi/URN:NBN:fi:oulu-202406264944
Tiivistelmä
Abstract
Introduction and aim:
Psoriasis vulgaris is associated with a significant healthcare burden, which increases over time as the disease progresses. The aim of this retrospective, population-based registry study was to characterize healthcare resource utilization (HCRU) in patients with psoriasis using biologics and oral immunosuppressants (conventionals) in Finland.
Materials and methods:
The study cohort included all patients with a diagnosis of psoriasis vulgaris in the secondary healthcare setting between 2012–2018, who initiated a biologic (n=1,297) or conventional (n=4,753) treatment between 2013–2017. Data on primary and secondary HCRU were collected from nationwide healthcare registries.
Results:
The results indicated a remarkable decrease in contacts with a dermatologist after the treatment initiation among patients starting biologic (mean annual number of contacts 5.4 per person before and 2.3 after the initiation), but not conventional (3.3 and 3.2) treatment. For conventional starters there was a high level of contacts with a dermatologist surrounding times of treatment switching, which was not observed for biologic starters.
Conclusion:
Overall, primary and other secondary care contacts did not decrease after the initiation or switch of treatment. The results highlight the importance of thorough consideration of the most optimal treatment alternatives, considering the overall disease burden to patients and healthcare systems.
Introduction and aim:
Psoriasis vulgaris is associated with a significant healthcare burden, which increases over time as the disease progresses. The aim of this retrospective, population-based registry study was to characterize healthcare resource utilization (HCRU) in patients with psoriasis using biologics and oral immunosuppressants (conventionals) in Finland.
Materials and methods:
The study cohort included all patients with a diagnosis of psoriasis vulgaris in the secondary healthcare setting between 2012–2018, who initiated a biologic (n=1,297) or conventional (n=4,753) treatment between 2013–2017. Data on primary and secondary HCRU were collected from nationwide healthcare registries.
Results:
The results indicated a remarkable decrease in contacts with a dermatologist after the treatment initiation among patients starting biologic (mean annual number of contacts 5.4 per person before and 2.3 after the initiation), but not conventional (3.3 and 3.2) treatment. For conventional starters there was a high level of contacts with a dermatologist surrounding times of treatment switching, which was not observed for biologic starters.
Conclusion:
Overall, primary and other secondary care contacts did not decrease after the initiation or switch of treatment. The results highlight the importance of thorough consideration of the most optimal treatment alternatives, considering the overall disease burden to patients and healthcare systems.
Kokoelmat
- Avoin saatavuus [38840]
Ellei muuten mainita, aineiston lisenssi on https://creativecommons.org/licenses/by/4.0/